Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Biomarkers predict progressive spinal damage in ankylosing spondylitis

Biomarkers predict progressive spinal damage in ankylosing spondylitis

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches new subtype specific antibody as marker for AS

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Questcor fourth quarter net sales increase to $75.5 million

Questcor fourth quarter net sales increase to $75.5 million

Study implicates 'arms race' between genes and germs

Study implicates 'arms race' between genes and germs

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

TNF inhibitors may minimally increase risk of serious infections

TNF inhibitors may minimally increase risk of serious infections

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Potential predictors of spinal damage progression in people with spondyloarthritis

Potential predictors of spinal damage progression in people with spondyloarthritis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.